Fluorinated tracers for imaging tumoral proliferation with positron emission tomography;Traceurs fluorés de la prolifération des cancers en tomographie par émission de positons

Medecine Nucleaire

Volumn 28, Issue 8, 2004, Pages 371-376

  Couturier, Olivier ^a   Bodet Milin, C ^a   Cherel, M ^b   Hustinx, R ^c  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c CHU SART TILMAN   (Belgium)

Author keywords

Cancer imaging; Fluorinated tracers; Positron emission tomography; Proliferation

Indexed keywords

1 (2 DEOXY 2 FLUORO 1 DEXTRO ARABINOFURANOSYL) 5 BROMOURACIL F 18; 2' FLUORO 5 METHYLDEOXYURACIL BETA DEXTRO ARABINOFURANOSYL F 18; 3' DEOXY 3' FLUOROTHYMIDINE F 18; 5 BROMOURACIL; AMINO ACID; CARBON 11; CHOLINE; CHOLINE C 11; FLUORINE 18; FLUORO ALPHA METHYLTYROSINE F 18; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE F 18; FLUOROETHYLDIMETHYL 2 OXYETHYLAMMONIUM FLUOROETHYLCHOLINE F 18; FLUOROMETHYLDIMETHYL 2 HYDROXYETHYLAMMONIUM FLUOROCHOLINE F 18; FLUOROMETHYLMETHYLETHYL 2 HYDROXYETHYLAMMONIUM FLUOROMETHYL(ETHYL)CHOLINE F 18; FLUOROPROPYLDIMETHYL 2 HYDROXYETHYLAMMONIUM FLUOROPROPYLCHOLINE F 18; FLUOROTYROSINE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; METHIONINE C 11; PHENYLALANINE; THYMIDINE; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TYROSINE; UNCLASSIFIED DRUG;

AUTORADIOGRAPHY; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOMA; CANCER; CARCINOID; CELL PROLIFERATION; CHRONIC PANCREATITIS; DRUG HALF LIFE; DRUG UPTAKE; GRANULATION TISSUE; HUMAN; LOW ENERGY RADIATION; MACROPHAGE; MELANOMA; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA;

EID: 6344277907     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Schirrmeister H et al. Immunostaging in pancreatic cancer and chronic active pancreatitis: does in vivo FDG-uptake correlate with proliferative activity? J Nucl Med 2001; 42: 721-725.
2. Kubota R et al. Intratumoral distribution of fluorine-18- fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
3. Brown RS, et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995; 36(10): 1854-1861.
4. Lewis P and Salama A Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-1649.
5. Patz EF Jr, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188(2): 487-490.
6. Kubota R et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995; 36: 484-492.
7. Wienhard K et al. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine [see comments]. J Nucl Med 1991; 32(7): 1338-1346.
8. Hustinx R et al. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. J Nucl Med 2003.; 44(4): 533-539.
9. Amano S et al. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Medicine 1998; 39(8): 1424-1427.
10. Inoue T et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha- methyl tyrosine: a potential tumor-detecting agent. J Nucl Med 1998; 39(4): 663-667.
11. Watanabe H et al. PET imaging of musculoskeletal tumours with fluorine-18-methyltyrosine: comparison with fluorine-18 fluorodeoxy-glucose PET. Eur J Nucl Med 2000; 27: 1509-1517.
12. Rau FC et al. O-(2-[18F]fluoro-ethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med 2002; 29: 1039-1046.
13. Schreckenberger M et al. First results of F-18-fluoroethyl-tyrosine PET for imaging of metastatic malignant melanoma. J Nucl Med 2001; 42: 30P
14. 18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000; 27: 542-549.
15. 18F] fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. J Nucl Med 2001. 42: 248-256.
16. Graham MM. Combined 18F-FDG-FDOPA tumor imaging for assessing response to therapy. J Nucl Med 2001. 42: 257-258.
17. Hoegerle S et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001. 28: 64-71.
18. Hoegerle S et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001. 220: 373-380.
19. Becherer A et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 2003. 30(11): 1561-1567.
20. Sakamoto S, Ebuchi M, and Iwama T. Relative activities of thymidylate synthetase and thymidine kinase in human mammary tumours. Anticancer Res 1993. 13: 205-207.
21. Sherr C and Roberts J. Inhibitors of mammalian G1 cycline-dependent kinases. Genes develop 1995; 9: 1149-1163.
22. Toyohara J et al. Basis of FLT as cell proliferattion marker comparative uptake studies with [3H]thymidine and [3H]arabinothy-midine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002; 29: 281-287.
23. Grierson J et al. Comparative uptake and cell cycle measurements with [18F]FLT vs. [3H]thymidine in mammalian tumor cells. J Nucl Med 1998; 39 (Supp.51): 229P-230P
24. Buck AK et al. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for non-invasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62(12): 3331-3334.
25. Buck AK et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003; 44(9): 1426-1431.
26. Dittmann H et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30(10): 1407-1412.
27. Francis DL et al. Potential impact of [18F]3′-deoxy-3′- fluoro-thymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30(7): 988-994.
28. Barthel H et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63(13): 3791-3798.
29. Dittmann H et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002; 29(11): 1462-1469.
30. Hara T. 18F-fluorocholine: a new oncologic PET tracer. J Nucl Med 2001; 42(12): 1815-1816.
31. Hara T et al. Imaging of brain tumor, lung cancer, esophagus cancer, colon cancer, prostate cancer, and bladder cancer with (HC)choline. J Nucl Med 1997; 38 (suppl): 250P.
32. Hara T and Yuasa M. Automated synthesis of fluorine-18 labeled choline analog: 2-fluoroethyl-dimethyl-2-oxyethylammonium. J Nucl Med 1997; 38((suppl)): 44P.
33. DeGrado TR et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2000;. 61(1): 110-117.
34. DeGrado T.R et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42(12): 1805-1814.
35. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Molecular Imaging Biology 2002; 4(4): 267-273.
36. Price DT et al. Comparison of [18 F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168(1): 273-280.
37. Hara T, Kosaka N and Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002. 43(2): 187-199.